$ABBV QuantLogix Newsdesk · June 29, 2026 at 4:31 PM UTC

ABBV Reaches 52-Week High at $253.92, Valuation Questions Emerge

What happened

AbbVie shares touched a fresh 52-week high on June 29, 2026, closing at $253.92 with a modest 0.19% daily gain. The milestone prompted analysis of whether the stock's valuation has extended beyond historically comfortable levels following the extended price run. AbbVie has been recovering earnings momentum after absorbing Humira biosimilar competition, with its newer immunology and oncology assets carrying growth expectations that now underpin the elevated price point.

The QL Read

The new high arrives in a cautious tape — breadth sitting at 43.2% advancing with decliners outpacing advancers 2834 to 2154. QuantLogix's composite for ABBV reads 60/100, a constructive but not aggressive level, indicating the signal supports the trend without flagging strong momentum acceleration at this price.

Source: The Motley Fool — "AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?" — 2026-06-29T15:21:30Z

Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.